New heart surgery combo could spare patients from open chest incision

NCT ID NCT05504031

Not yet recruiting Disease control Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will compare a newer, less invasive heart procedure called hybrid revascularization to standard coronary artery bypass grafting (CABG) in over 1,000 people with multiple blocked heart arteries. The hybrid approach combines a small incision to graft a key artery with stents to open other blockages, avoiding a full chest opening. The goal is to see if it is as safe and effective as traditional bypass surgery in preventing death, heart attacks, strokes, and hospital stays.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hybrid coronary revascularization (minimally invasive heart surgery combined with stenting)
What this could lead to: If successful, this could offer a less invasive alternative to open-heart bypass surgery for people with multiple blocked heart arteries, potentially leading to faster recovery and fewer complications.
What could go wrong: This is a large, well-designed trial, but it hasn't started yet. The hybrid approach is complex and may not prove as durable or safe as standard bypass surgery over the long term. There are also risks of bleeding, infection, and heart attack with both procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

Contacts and locations

Locations

Rigshospitalet

Copenhagen, Capital Region, 2100, Denmark
UMC Utrecht

Utrecht, Netherlands
UZ Leuven

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.